UY33738A - Compound 8-oxo-9- [3- (1H-benzimidazol-2-yloxy) -phenyl] -4,5,6,7,8,9-hexahydro-2H-pyrrolo [3,4-b] quinoline-3 -ethyl carboxylate, its salts and preparation methods. - Google Patents

Compound 8-oxo-9- [3- (1H-benzimidazol-2-yloxy) -phenyl] -4,5,6,7,8,9-hexahydro-2H-pyrrolo [3,4-b] quinoline-3 -ethyl carboxylate, its salts and preparation methods.

Info

Publication number
UY33738A
UY33738A UY0001033738A UY33738A UY33738A UY 33738 A UY33738 A UY 33738A UY 0001033738 A UY0001033738 A UY 0001033738A UY 33738 A UY33738 A UY 33738A UY 33738 A UY33738 A UY 33738A
Authority
UY
Uruguay
Prior art keywords
benzimidazol
pyrrolo
hexahydro
yloxy
oxo
Prior art date
Application number
UY0001033738A
Other languages
Spanish (es)
Inventor
Pascal Billot
Carry Jean-Christophe
Nathalie Arokiassamy
Patrick Clavieres
Clerc Francois
Crocq-Stuerga Veronique
Sylvette Lachaud
Philippe Lienard
Menegotto Jerome
Laurent Schio
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33738A publication Critical patent/UY33738A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La invención se refiere más precisamente a una nueva sal, co-cristal y formulaciones de 8-oxo-9-[3-(1H-bencimidazol-2-iloxi)-fenil]-4,5,6,7,8,9-hexahidro-2H-pirrolo[3,4-b]quinolina-3-carboxilato de etilo de fórmula (F) a sus preparaciones y a su utilización en terapéutica, principalmente como inhibidores selectivos de las quinasas Aurora A y B, y para su utilización como anticancerosos.The invention relates more precisely to a new salt, co-crystal and formulations of 8-oxo-9- [3- (1 H -benzimidazol-2-yloxy) -phenyl] -4,5,6,7,8,9 -hexahydro-2H-pyrrolo [3,4-b] ethyl quinoline-3-carboxylate of formula (F) to its preparations and its use in therapeutics, mainly as selective inhibitors of Aurora A and B kinases, and for use as anticancer.

UY0001033738A 2010-11-17 2011-11-17 Compound 8-oxo-9- [3- (1H-benzimidazol-2-yloxy) -phenyl] -4,5,6,7,8,9-hexahydro-2H-pyrrolo [3,4-b] quinoline-3 -ethyl carboxylate, its salts and preparation methods. UY33738A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1059456A FR2967413A1 (en) 2010-11-17 2010-11-17 COMPOUND 8-OXO-9- [3- (1H-BENZIMIDAZOL-2-YLOXY) -PHENYL] -4,5,6,7,8,9-HEXAHYDRO-2H-PYRROLO [3,4-B] QUINOLIN-3 - ETHYL CARBOXYLATE, SALT, CRYSTALLINE FORM, CO-CRYSTAL, FORMULATION, METHODS OF PREPARATION, MEDICAMENT APPLICATION, PHARMACEUTICAL COMPOSITIONS, AND NOVEL USE, IN PARTICULAR AS THE INHIBITOR OF AURORA KINASES.

Publications (1)

Publication Number Publication Date
UY33738A true UY33738A (en) 2012-06-29

Family

ID=43759999

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033738A UY33738A (en) 2010-11-17 2011-11-17 Compound 8-oxo-9- [3- (1H-benzimidazol-2-yloxy) -phenyl] -4,5,6,7,8,9-hexahydro-2H-pyrrolo [3,4-b] quinoline-3 -ethyl carboxylate, its salts and preparation methods.

Country Status (5)

Country Link
AR (1) AR083901A1 (en)
FR (1) FR2967413A1 (en)
TW (1) TW201307339A (en)
UY (1) UY33738A (en)
WO (1) WO2012066486A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1746097T3 (en) * 2005-07-20 2010-05-25 Aventis Pharma Sa 1,4-dihydropyridine-fused heterocyclic rings, process for their preparation, use and compositions containing them
FR2945535B1 (en) * 2009-05-18 2011-06-10 Sanofi Aventis ANTICANCER COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Also Published As

Publication number Publication date
FR2967413A1 (en) 2012-05-18
AR083901A1 (en) 2013-04-10
WO2012066486A1 (en) 2012-05-24
TW201307339A (en) 2013-02-16

Similar Documents

Publication Publication Date Title
PH12015500260A1 (en) Neprilysin inhibitors
CO6741203A2 (en) Bicyclo derivatives [3,2,1] octylamide and their uses
MX342212B (en) Substituted aminobutyric derivatives as neprilysin inhibitors.
PH12014502733A1 (en) Neprilysin inhibitors
MX360634B (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof.
MY165087A (en) Neprilysin inhibitors
DOP2014000204A (en) HETEROCICLYL COMPOUNDS AS MEK INHIBITORS
UY35683A (en) POLYMORPH OF INHIBITORS OF TIROSINA KINASA OF BAZO (SYK)
EP4289813A3 (en) Intermediates to obtain substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
MX2014001885A (en) 5-FLUORO-4-IMINO-3-(SUBSTITUTED)-3,4-DIHYDROPYRIMIDIN-2-(1H</ i>)-ONE DERIVATIVES.
EA201291409A1 (en) DERIVATIVES OF INDOLYSINE, METHOD OF THEIR PRODUCTION AND THEIR THERAPEUTIC APPLICATION
UA117122C2 (en) Novel quinolone derivatives
CY1123456T1 (en) METHOD OF PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROME-4-ONE DERIVATIVES AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
AR088018A1 (en) PROCESS AND INTERMEDIARIES TO PREPARE LAPATINIB
IN2015DN01119A (en)
CO7280475A2 (en) Azaindole derivatives that act as pi3k inhibitors
UY34380A (en) ? DETERMINATION OF SIMPLE NUCLEOTIDE POLYMORPHYSMS USEFUL TO PREACH THE CLINICAL RESPONSE TO GLATIRAMBER ACETATE ?.
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
AR092971A1 (en) AGRECANASA INHIBITORS
ECSP13012548A (en) OXADIAZOL INHIBITORS OF LEUCOTRENE PRODUCTION.
CU20110108A7 (en) [4- (1-AMINO-ETIL) -CICLOHEXIL] -METIL-AMINAS AS ANTIBACTERIALS
UA109804C2 (en) 2-methoxypyridine-4-yl derivatives
ECSP13013080A (en) USEFUL PIRAZOL DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
UY33738A (en) Compound 8-oxo-9- [3- (1H-benzimidazol-2-yloxy) -phenyl] -4,5,6,7,8,9-hexahydro-2H-pyrrolo [3,4-b] quinoline-3 -ethyl carboxylate, its salts and preparation methods.